BioStem Technologies (OTCMKTS:BSEM) Shares Down 0.2% - Should You Sell?

Key Points

• BioStem Technologies (OTCMKTS:BSEM) stock price decreased by 0.2%, trading between $10.00 and $10.35 with an increase in trading volume of 3% from the average.
• The company reported a quarterly earnings per share (EPS) of $0.17, missing analysts' expectations significantly of $1.25, and revenue of $72.53 million, below the $101.20 million estimate.
• BioStem Technologies has a market capitalization of $173.36 million and a P/E ratio of 7.04, indicative of its current valuation in the market.

BioStem Technologies, Inc. (OTCMKTS:BSEM - Get Free Report)'s stock price fell 0.2% during trading on Friday . The company traded as low as $10.00 and last traded at $10.35. 49,797 shares were traded during mid-day trading, an increase of 3% from the average session volume of 48,389 shares. The stock had previously closed at $10.37.

BioStem Technologies Price Performance

The firm's 50 day moving average price is $12.21 and its 200-day moving average price is $12.37. The firm has a market cap of $177.47 million, a price-to-earnings ratio of 7.21 and a beta of -0.29.

BioStem Technologies (OTCMKTS:BSEM - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $1.25 by ($1.08). The business had revenue of $72.53 million for the quarter, compared to analysts' expectations of $101.20 million. Analysts expect that BioStem Technologies, Inc. will post 1.41 EPS for the current year.

About BioStem Technologies

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.